Literature DB >> 6742977

Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder.

D S Charney, G R Heninger, A Breier.   

Abstract

Yohimbine, an alpha 2-adrenergic receptor antagonist that increases noradrenergic function, was administered to 20 healthy subjects and 39 drug-free patients with agoraphobia and panic attacks. Following drug administration, changes in plasma levels of the norepinephrine metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG), BP, pulse rate, and subjective ratings of feelings and somatic symptoms were examined during a four-hour period. Yohimbine produced significantly greater increases in patient-rated anxiety, nervousness, palpitations, hot and cold flashes, restlessness, tremors, piloerection, and sitting systolic BP in the total patient group compared with healthy subjects. There were significant correlations between the yohimbine-induced rise in plasma MHPG level and patient-rated anxiety and nervousness and the frequency of reported panic attacks. Patients experiencing frequent panic attacks (greater than 2.5 per week) had a significantly greater plasma MHPG response to yohimbine than the healthy subjects and patients having less frequent panic attacks. These observations support a hypothesis of increased sensitivity to augmented noradrenergic function in anxiety states associated with panic, and they suggest that impaired presynaptic noradrenergic neuronal regulation may exist in patients with frequent panic attacks.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6742977     DOI: 10.1001/archpsyc.1984.01790190025003

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  71 in total

1.  Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers.

Authors:  S T Szabo; C de Montigny; P Blier
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

2.  Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans.

Authors:  Christian Grillon; Jeremy Cordova; Louise R Levine; Charles A Morgan
Journal:  Psychopharmacology (Berl)       Date:  2003-04-23       Impact factor: 4.530

3.  Effects of the beta-blocker propranolol on cued and contextual fear conditioning in humans.

Authors:  Christian Grillon; Jeremy Cordova; Charles Andrew Morgan; Dennis S Charney; Michael Davis
Journal:  Psychopharmacology (Berl)       Date:  2004-09       Impact factor: 4.530

4.  Effects of yohimbine in obsessive compulsive disorder.

Authors:  S A Rasmussen; W K Goodman; S W Woods; G R Heninger; D S Charney
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Dysfunctional baroreflex regulation of sympathetic nerve activity in remitted patients with panic disorder. A new methodological approach.

Authors:  Toshiki Shioiri; Maki Kojima-Maruyama; Toshihiro Hosoki; Hideaki Kitamura; Akira Tanaka; Makoto Yoshizawa; Takehiko Bando; Toshiyuki Someya
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-01-14       Impact factor: 5.270

6.  Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults.

Authors:  Roma A Vasa; Daniel S Pine; Carrie L Masten; Meena Vythilingam; Carlos Collin; Dennis S Charney; Alexander Neumeister; Karin Mogg; Brendan P Bradley; Maggie Bruck; Christopher S Monk
Journal:  Psychopharmacology (Berl)       Date:  2009-03-06       Impact factor: 4.530

Review 7.  Serotonin selectivity for obsessive compulsive and panic disorders.

Authors:  S A Montgomery; T Bullock; N Fineberg
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

8.  Melatonin responses to clonidine and yohimbine challenges.

Authors:  S H Kennedy; W Gnam; E Ralevski; G M Brown
Journal:  J Psychiatry Neurosci       Date:  1995-07       Impact factor: 6.186

9.  Evaluation of the alpha 2-adrenoceptor blocking properties of buspirone and ipsapirone in healthy subjects. Relationship with the plasma concentration of the common metabolite 1-(2-pyrimidinyl)-piperazine.

Authors:  I Berlin; S Chalon; C Payan; G Schöllnhammer; F Cesselin; O Varoquaux; A J Puech
Journal:  Br J Clin Pharmacol       Date:  1995-03       Impact factor: 4.335

10.  Noradrenergic response to acute ethanol administration in healthy subjects: comparison with intravenous yohimbine.

Authors:  C J McDougle; J H Krystal; L H Price; G R Heninger; D S Charney
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.